| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.02 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.091 | 0.02 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.02 |